Urteste SA
WSE:URT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Urteste SA
Gross Profit
Urteste SA
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
U
|
Urteste SA
WSE:URT
|
Gross Profit
-zł298k
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mabion SA
WSE:MAB
|
Gross Profit
-zł26.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-27%
|
|
|
R
|
Read Gene SA
WSE:RDG
|
Gross Profit
zł14.6m
|
CAGR 3-Years
33%
|
CAGR 5-Years
21%
|
CAGR 10-Years
57%
|
|
|
G
|
Genomed SA
WSE:GEN
|
Gross Profit
zł19.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
24%
|
CAGR 10-Years
21%
|
|
|
B
|
Bioton SA
WSE:BIO
|
Gross Profit
zł91.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Gross Profit
zł33m
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
Urteste SA
Glance View
Urteste SA specializes in the development of technology that allows the detection of cancers at early stages of their development. The company is headquartered in Gdansk, Woj. Pomorskie. The company went IPO on 2021-10-27. The firm operates in the field of medical devices for in vitro application in the field of cancer diagnostics. The technology developed by the Company involves the detection of cancer by measuring the activity of enzymes in a urine sample, using diagnostic tests that enable the detection of common cancers in their early stages. The firm offers tests for the detection of cancers such as, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, stomach cancer, esophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukemia, lymphoma, glioma.
See Also
What is Urteste SA's Gross Profit?
Gross Profit
-298k
PLN
Based on the financial report for Dec 31, 2024, Urteste SA's Gross Profit amounts to -298k PLN.
What is Urteste SA's Gross Profit growth rate?
Gross Profit CAGR 5Y
-58%
Over the last year, the Gross Profit growth was 38%. The average annual Gross Profit growth rates for Urteste SA have been -37% over the past three years , -58% over the past five years .
